Navigation Links
Echo Therapeutics Reports Third Quarter 2007 Results
Date:11/20/2007

323,078 803,754 923,172 2,489,996

Purchased research

and development 6,556,048 - 6,556,048 -

Selling, general

and administrative 1,767,587 622,518 2,812,002 1,843,534

Total operating

expenses 8,646,713 1,435,717 10,292,778 4,395,264

Loss from operations (8,634,213) (1,412,538) (10,243,158) (4,320,144)

Other income (Expense):

Interest income 21,657 28,604 35,563 109,687

Interest expense (64,131) (4,469) (70,289) (14,439)

Other income, net (42,474) 24,135 (34,726) 95,248

Net loss (8,676,687) (1,388,403) (10,277,884) (4,224,896)

Accretion of dividend on

Series A Convertible

Preferred Stock - (1,479) (483) (4,389)

Net loss applicable

to common

shareholders $(8,676,687) $(1,389,882) $(10,278,367) $(4,229,285)

Net loss per common share,

basic and diluted $(0.70) $(0.49) $(1.05) $(1.60)

Basic and diluted weighted

average common shares

outstanding 12,438,201 2,839,201 9,771,183 2,640,691


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
(Date:7/24/2014)... 2014 Gain recognition for leadership ... of the biotech industry. Nominations are now being ... to you by the Bio Supply Management ... chain management professionals for the past 7 years. ... the Biotech industry – Manufacturers, Service Providers, Material ...
(Date:7/24/2014)... 24, 2014  ECC West Africa, LLC (ECC) signed ... with University College Hospital (UCH) Ibadan Board of Management ... finance, design, construct, and operate and maintain a new, ... . Under the first of the 4-phase project, ECC ... funding applications. UCH Ibadan intends to finance and develop ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... caused by mutations in the gene responsible for making ... and developing new therapies has been hampered by the ... fail to develop many of the symptoms seen in ... April issue of the Journal of Clinical Investigation have ...
... 6 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq: PXSL) today ... treat bronchiectasis has been accepted for evaluation by,China,s ... pharmaceutical companies are required to undertake a study ... application.,Approval of the clinical trial application is expected ...
... PALO ALTO, Calif., March 6 Jazz,Pharmaceuticals, Inc. ... the,public to a live webcast of the company,s ... 10:00 a.m. Eastern Time/7:00 a.m.,Pacific Time on Thursday, ... last,approximately two hours., Members of Jazz Pharmaceuticals, ...
Cached Biology Technology:Pharmaxis' First Steps into China 2
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
(Date:7/24/2014)... 3.5 billion years of evolutionary trial and error, is ... may be reaching a tipping point. , In a ... published in Science , an international team of ... is contributing to what appears to be the early ... , Since 1500, more than 320 terrestrial vertebrates have ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... of the body, the great majority of genes are silenced, ... up chromosomes. Estimates are that only about 10 percent of ... or "on," at any given time in a particular cell ... , Reliable gene silencing is vital to the health of ...
... have discovered a gene in fruit flies that helps ... The study, published in the April 4 issue of ... in mammals. , In teasing apart the molecular interactions ... gene they dubbed "Lazaro" that is expressed 15 times ...
... industry, including cruise lines, local governments and shore ... are taking proactive measures to ensure a sustainable ... according to a new report titled From Ship ... by Conservation International's (CI) Center for Environmental Leadership ...
Cached Biology News:New mechanism for essential genome-wide gene silencing identified 2New gene reduces retinal degeneration in fruit flies 2Report finds cruise industry is protecting the precious places it visits 2Report finds cruise industry is protecting the precious places it visits 3Report finds cruise industry is protecting the precious places it visits 4
...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
Anti-Salmonid Ig (H), Alk Phos, (Clone IPA5F12) (mouse IgG2a)...
Biology Products: